Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > December 13, 2022
Daily News
December 13, 2022
- Daiichi Sankyo’s TROP2-Directed ADC Shows Promising Data for Triple Negative Breast Cancer
December 13, 2022
- LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
- LDP Committee Insists on Better Handling of Innovative Drugs, Unprofitable Meds in Off-Year Re-Pricing
December 13, 2022
- LDP League, MHLW Discussing to Create Forum to Study SaMD Reimbursement
December 13, 2022
- Paper Retraction Won’t Impact Zolgensma Japan Approval, Data Deleted from Label
December 13, 2022
- Yescarta, Breyanzi Clear Panel Review for Second-Line Use
December 13, 2022
- Estimated 1,024 Patients Took Xocova in First 11 Days: Shionogi
December 13, 2022
- Japan Panel Recognizes 5 More Deaths Possibly Linked to COVID Jabs, 1st for 20s
December 13, 2022
- RaQualia, DWTI Tie Up on Eye Disease Drug Research
December 13, 2022
- Japan’s Diet Enacts Bill to Amend Intractable Disease Law
December 13, 2022
- Minimum Age for Moderna Boosters Lowered to 12 Years Old in Japan
December 13, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…